Analysts Set Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Target Price at $177.00

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) has earned an average recommendation of “Moderate Buy” from the fifteen ratings firms that are covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating on the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $177.00.

A number of analysts have recently issued reports on JAZZ shares. Piper Sandler reaffirmed an “overweight” rating and set a $163.00 target price on shares of Jazz Pharmaceuticals in a research report on Thursday, December 12th. Robert W. Baird upped their target price on Jazz Pharmaceuticals from $154.00 to $162.00 and gave the company an “outperform” rating in a research report on Monday, November 18th. HC Wainwright reissued a “buy” rating and set a $200.00 price target on shares of Jazz Pharmaceuticals in a research report on Friday, November 22nd. Morgan Stanley raised shares of Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and upped their price target for the company from $140.00 to $175.00 in a report on Thursday, December 12th. Finally, TD Cowen decreased their price objective on shares of Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating for the company in a report on Thursday, November 7th.

Jazz Pharmaceuticals Price Performance

JAZZ opened at $122.54 on Friday. Jazz Pharmaceuticals has a twelve month low of $99.06 and a twelve month high of $134.17. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46. The firm has a market cap of $7.41 billion, a price-to-earnings ratio of 17.26, a PEG ratio of 1.04 and a beta of 0.56. The company has a fifty day simple moving average of $121.45 and a 200 day simple moving average of $113.89.

Insider Activity

In other news, CEO Bruce C. Cozadd sold 1,500 shares of the business’s stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $123.43, for a total transaction of $185,145.00. Following the completion of the transaction, the chief executive officer now owns 425,525 shares of the company’s stock, valued at approximately $52,522,550.75. The trade was a 0.35 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, EVP Neena M. Patil sold 3,700 shares of the stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $123.41, for a total transaction of $456,617.00. Following the completion of the sale, the executive vice president now directly owns 33,048 shares in the company, valued at approximately $4,078,453.68. This trade represents a 10.07 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 8,253 shares of company stock valued at $1,001,434. 4.20% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Jazz Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Everence Capital Management Inc. acquired a new position in Jazz Pharmaceuticals during the 4th quarter worth $277,000. Centre Asset Management LLC acquired a new stake in Jazz Pharmaceuticals in the fourth quarter worth about $9,335,000. GAMMA Investing LLC grew its position in Jazz Pharmaceuticals by 49.8% in the 4th quarter. GAMMA Investing LLC now owns 620 shares of the specialty pharmaceutical company’s stock valued at $76,000 after buying an additional 206 shares in the last quarter. Versant Capital Management Inc increased its stake in Jazz Pharmaceuticals by 56.7% during the 4th quarter. Versant Capital Management Inc now owns 967 shares of the specialty pharmaceutical company’s stock valued at $119,000 after buying an additional 350 shares during the period. Finally, Franklin Resources Inc. raised its position in shares of Jazz Pharmaceuticals by 4.6% during the 3rd quarter. Franklin Resources Inc. now owns 1,118,688 shares of the specialty pharmaceutical company’s stock worth $124,208,000 after buying an additional 48,708 shares in the last quarter. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.